Onabotulinumtoxin A

ApprovedSmall molecule

Lundbeck

Onabotulinumtoxin A is one of 179 small molecule programs targeting Tremor. It is currently in Approved.

Indications

Total Trials

Active Trials

178

Competitors

Pipeline

Status by Indication[3][1]

Indication

TremorActive, not recruiting

Stress Urinary IncontinenceActive, not recruiting

Interstitial CystitisActive, not recruiting

MigraineActive, not recruiting

SclerodermaActive, not recruiting

Spinal Cord InjuryActive, not recruiting

TremorPhase 2

Active, not recruiting

Stress Urinary IncontinencePhase 1

Active, not recruiting

Interstitial CystitisApproved

Active, not recruiting

MigraineApproved

Active, not recruiting

SclerodermaPhase 3

Active, not recruiting

Spinal Cord InjuryApproved

Active, not recruiting

Competition

Competitive Landscape

357 competitors in Migraine

#DrugCompanyPhaseTrials

Onabotulinumtoxin A

Lundbeck

Approved

1 2

Aimovig

Amgen

Preclinical

33 3

Savella

AbbVie

Preclinical

2 4

Adempas

Bayer

Preclinical

1 5

Botox

RRevance Therapeutics, Inc.

Preclinical

9 6

Cervidil

Pfizer

Preclinical

1 7

Nitrostat

VViatris Specialty LLC

Preclinical

2 8

Viagra

VViatris Specialty LLC

Preclinical

2 9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 10

Pristiq

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Scleroderma1 trial

Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome

Completed·JJohns Hopkins University·Phase 3·NCT02165111·40 enrolled

Spinal Cord Injury1 trial

Prevention of Bladder Dysfunction in Acute Spinal Cord Injury

Completed·OOslo University Hospital·Phase 4·NCT01698138·20 enrolled

Migraine1 trial

Real World Effectiveness of Eptinezumab in Participants With Migraine

Terminated· Lundbeck logo

Lundbeck·Phase 4·NCT05284019·32 enrolled

Stress urinary incontinence1 trial

Feasibility of BOTOX Injection on Improving Female Stress Urinary Incontinence

Suspended·NNorthwell Health·Phase 1·NCT04984317·20 enrolled

Chronic Pelvic Pain1 trial

Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain

Completed·—·N/A·NCT02369068·21 enrolled

3 more indications

Interstitial Cystitis1 trial

Intravesicular Onabotulinumtoxin A in Interstitial Cystitis

Completed·WWake Forest University Health Sciences·Phase 4·NCT02297100·27 enrolled

Pain1 trial

Reduction of Bladder Injection Pain With Belladonna Opiate Suppository

Completed·—·Phase 4·NCT02600715·26 enrolled

Tremor1 trial

Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT03301272·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Onabotulinumtoxin A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Onabotulinumtoxin A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Onabotulinumtoxin A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lundbeck company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Lundbeck

Onabotulinumtoxin A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Scleroderma1 trial

Spinal Cord Injury1 trial

Migraine1 trial

Stress urinary incontinence1 trial

Chronic Pelvic Pain1 trial

Interstitial Cystitis1 trial

Pain1 trial

Tremor1 trial

References

Drug Info

Quick Facts

Related News